[CAS NO. 428863-50-7] Certolizumab pegol

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [428863-50-7]

Catalog

HY-P9953

Brand

MCE

CAS

428863-50-7

DESCRIPTION [428863-50-7]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Certolizumab]

For research use only. We do not sell to patients.

Summary

Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α ( TNF-α ). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research ^[1] ^[2] .

In Vitro

Certolizumab pegol (Certolizumab) neutralizes soluble TNFα with an IC ₉₀ of 3 ng/mL ^[2] .
Certolizumab pegol (0-100 μg/mL, 1 h) completely inhibits subsequent production of IL-1β in response to LPS at concentrations over 1μg/mL in human monocytes ^[2] .
Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) ^[2] .
Certolizumab pegol does not induce apoptosis of activated human monocytes or peripheral blood lymphocytes (PBLs) or result in degranulation or loss of cell membrane integrity in polymorphonuclear cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Certolizumab pegol (Certolizumab) (10 μg; i.p.; single dose) reduces the severity of acute pancreatitis ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals) ^[3]
Dosage:	10 μg
Administration:	Intraperitoneal administration, single dose
Result:	Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01295151	Julia Brown\|University of Leeds	Rheumatoid Arthritis	August 2011	Phase 4
NCT01098201	University of Rochester	Rheumatoid Arthritis	October 2010
NCT01374971	Nathan Wei, MD, FACP, FACR:\|University of California, San Diego\|Arthritis Treatment Center, Maryland	Rheumatoid Arthritis	September 2011	Phase 3
NCT01582568	Baylor College of Medicine\|UCB Pharma	Crohns Disease	June 2011
NCT03100253	Mario Negri Institute for Pharmacological Research	Rheumatoid Arthritis	March 1, 2018	Phase 4
NCT00993317	Korea Otsuka Pharmaceutical Co., Ltd.	Rheumatoid Arthritis	October 2009	Phase 3
NCT03955861	Belfast Health and Social Care Trust\|British Medical Association\|Psoriasis and Psoriatic Arthritis Alliance\|Queen´s University, Belfast	Psoriatic Arthritis\|Psoriasis\|Enthesitis	February 14, 2019
NCT00845663	UCB Pharma	Healthy	October 2007	Phase 1
NCT02326298	UCB Biopharma S.P.R.L.\|UCB Pharma	Psoriasis\|Plaque Psoriasis	December 16, 2014	Phase 3
NCT03293784	Institut Claudius Regaud	Melanoma	October 16, 2017	Phase 1
NCT02132234	Jagiellonian University\|Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland	Rheumatoid Arthritis\|Psoriatic Arthritis\|Ankylosing Spondylitis\|Hypertension	June 2013	Phase 4
NCT01255761	UCB Pharma	Rheumatoid Arthritis	November 2010	Phase 4
NCT00851318	Astellas Pharma Inc\|UCB Japan Co. Ltd.	Rheumatoid Arthritis	March 2009	Phase 3
NCT00329420	UCB Pharma	Crohn´s Disease	May 2006	Phase 2
NCT00544154	UCB Pharma	Arthritis, Rheumatoid	October 2002	Phase 3
NCT03559660	UCB Biopharma S.P.R.L.\|UCB Pharma	Crohn´s Disease
NCT02073526	Oslo University Hospital	Inflammatory Bowel Disease\|Crohn´s Disease\|Ulcerative Colitis	May 2013
NCT00674362	UCB Pharma	Rheumatoid Arthritis	June 2008	Phase 3
NCT02552212	UCB BIOSCIENCES GmbH\|UCB Pharma	Axial Spondyloarthritis\|Nonradiographic Axial Spondyloarthritis\|Nr-axSpA	September 2015	Phase 3
NCT04569890	RenJi Hospital	Rheumatoid Arthritis\|Pregnancy Related	December 1, 2020	Not Applicable
NCT02497976	ICStudy, LLC\|UCB Pharma	Cystitis, Interstitial	December 15, 2015	Phase 3
NCT02714881	Brigham and Women´s Hospital	Rheumatoid Arthritis\|Cardiovascular Disease	April 2016	Not Applicable
NCT00160602	UCB Pharma	Rheumatoid Arthritis	June 2005	Phase 3
NCT00307931	UCB Pharma	Crohn´s Disease	April 2007	Phase 3
NCT02154425	UCB BIOSCIENCES, Inc.\|PPD\|Parexel\|UCB Pharma	Axial Spondyloarthritis (AxSpA)\|Non-radiographic Evidence-AxSpA\|Ankylosing Spondylitis\|Crohn´s Disease\|Psoriatic Arthritis\|Rheumatoid Arthritis	September 2014	Phase 1
NCT00791921	Otsuka Pharmaceutical Co., Ltd.\|UCB Japan Co. Ltd.	Rheumatoid Arthritis	November 2008	Phase 3
NCT02319642	UCB Pharma SA\|Parexel\|UCB Pharma	Rheumatoid Arthritis	November 2014	Phase 3
NCT00791999	Otsuka Pharmaceutical Co., Ltd.\|UCB Japan Co. Ltd.	Rheumatoid Arthritis	November 2008	Phase 2\|Phase 3
NCT01197066	Korea Otsuka Pharmaceutical Co., Ltd.	Rheumatoid Arthritis	March 2010	Phase 3
NCT00349752	UCB Pharma	Crohn´s Disease	November 2006	Phase 3
NCT00329550	UCB Japan Co. Ltd.\|UCB Pharma	Crohn´s Disease	May 2006	Phase 2
NCT00329303	UCB Pharma	Psoriasis	April 2006	Phase 2
NCT01817972	Gastroenterology Research of America\|UCB Pharma	Crohn´s Disease	March 2013	Phase 3
NCT01521923	UCB Pharma	Rheumatoid Arthritis	January 2012	Phase 3
NCT04725422	Seattle Children´s Hospital\|Boston Children´s Hospital, Boston, MA, USA\|Hospital for Special Surgery, New York City, NY, USA\|Joseph M Sanzari Children´s Hospital, Hackensack University Medical Center, Hackensack, NJ, USA\|Riley Children´s Hospital, Indianapolis, IN, USA\|University of North Carolina, Chapel Hill, NC, USA\|Royal Children´s Hospital, Melbourne, Australia\|Hacettepe University, Ankara, Turkey\|Bambino Gesù Children´s Hospital, Rome, Italy\|University of British Columbia, Vancouver, BC, Canada\|Meyer Children´s Hospital, Florence, Italy\|Mansoura University	Chronic Nonbacterial Osteomyelitis\|Chronic Recurrent Multifocal Osteomyelitis	August 1, 2018
NCT02019602	UCB BIOSCIENCES, Inc.\|PPD\|Parexel\|UCB Pharma	Axial Spondyloarthritis (AxSpA)\|Non-radiographic Evidence-AxSpA\|Ankylosing Spondylitis\|Crohn´s Disease\|Psoriatic Arthritis\|Rheumatoid Arthritis	January 2014	Phase 1
NCT00850343	Astellas Pharma Inc\|UCB Japan Co. Ltd.	Rheumatoid Arthritis	March 2009	Phase 3
NCT00356408	UCB Pharma	Crohn´s Disease	January 2007	Phase 3
NCT00245765	UCB Pharma	Chronic Plaque Psoriasis	October 2005	Phase 2
NCT03020992	UCB Biopharma SRL\|UCB Pharma	Axial Spondyloarthritis (axSpA)\|Anterior Uveitis (AU)	December 21, 2016	Phase 4
NCT00308581	UCB Pharma	Crohn´s Disease	April 2006	Phase 3
NCT01550003	UCB BIOSCIENCES GmbH\|PRA Health Sciences\|UCB Pharma	Polyarticular-course Juvenile Idiopathic Arthritis (JIA)	March 8, 2012	Phase 3
NCT00160693	UCB Pharma	Rheumatoid Arthritis	March 2003	Phase 3
NCT00297648	UCB Pharma	Crohn´s Disease	February 2006	Phase 3
NCT01091220	UCB Pharma	Sperm Quality	March 2010	Phase 1
NCT00548834	UCB Pharma	Rheumatoid Arthritis	June 2003	Phase 3
NCT02293590	Rüdiger B. Müller\|UCB Pharma\|Cantonal Hospital of St. Gallen	Rheumatoid Arthritis	November 2013	Phase 2
NCT00843778	UCB Pharma	Rheumatoid Arthritis	January 2009	Phase 3
NCT01053559	Shafran Gastroenterology Center\|UCB Pharma	Crohn´s Disease	January 2010	Not Applicable
NCT01292265	UCB Pharma	Rheumatoid Arthritis	February 2011	Phase 3
NCT00717236	UCB Pharma	Rheumatoid Arthritis	July 2008	Phase 3
NCT00152425	UCB Pharma	Crohn´s Disease	February 2004	Phase 3
NCT01443364	UCB Italy s.p.a.\|UCB Pharma	Rheumatoid Arthritis	December 2011	Phase 4
NCT00291668	UCB Pharma	Crohn´s Disease	March 2, 2006	Phase 2
NCT00152490	UCB Pharma	Crohn´s Disease	December 2003	Phase 3
NCT02451748	University of Illinois at Chicago\|UCB Pharma	Rheumatoid Arthritis	August 2015	Phase 4
NCT00333788	UCB Pharma	Crohn´s Disease	October 2006	Phase 3
NCT00160524	UCB Pharma SA\|UCB Pharma	Crohn´s Disease	July 2004	Phase 3
NCT04610476	University of Erlangen-Nürnberg Medical School	Psoriatic Arthritis\|Withdrawal\|Reduction	October 19, 2020	Phase 3
NCT02430909	UCB Celltech\|PRA Health Sciences\|UCB Pharma	Rheumatoid Arthritis	April 2015	Phase 2
NCT01519791	UCB Pharma SA\|UCB Pharma	Rheumatoid Arthritis	January 2012	Phase 3
NCT02365948	UCB Pharma SA\|Parexel\|UCB Pharma	Healthy Subjects	March 2015	Phase 1
NCT03215277	UCB Biopharma S.P.R.L.\|UCB Pharma	Ankylosing Spondylitis	October 4, 2017	Phase 2
NCT04991025	Memorial Sloan Kettering Cancer Center	Lung Cancer\|Lung Cancer Stage II\|Lung Cancer Stage III	October 19, 2022	Phase 2
NCT00580840	UCB Pharma	Rheumatoid Arthritis	December 2007	Phase 4
NCT03559686	UCB Biopharma S.P.R.L.\|UCB Pharma	Rheumatoid Arthritis
NCT02120807	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Stage IV Lung Adenocarcinoma	April 2014	Phase 1
NCT01864265	University of Erlangen-Nürnberg Medical School	Rheumatoid Arthritis	July 2013	Phase 3
NCT02586246	Astellas Pharma Inc\|UCB Japan Co. Ltd.	Active Rheumatoid Arthritis	January 2011	Phase 3
NCT02326272	UCB Biopharma S.P.R.L.\|UCB Pharma	Psoriasis\|Plaque Psoriasis	December 15, 2014	Phase 3
NCT03152058	David Ware Branch\|Hospital for Special Surgery, New York\|University of Toronto\|NYU Langone Health\|University of Utah	High Risk Pregnancy\|Pregnancy Complications\|Antiphospholipid Syndrome in Pregnancy\|Lupus Anticoagulant Disorder	May 17, 2017	Phase 2
NCT01235598	UCB Pharma	Rheumatoid Arthritis	December 2010	Phase 3
NCT04163016	UCB Biopharma S.P.R.L.\|UCB Pharma	Rheumatoid Arthritis\|Psoriatic Arthritis\|Crohn´s Disease\|Axial Spondyloarthritis\|Plaque Psoriasis	June 19, 2020	Phase 1
NCT01500278	UCB Pharma SA\|Parexel\|UCB Pharma	Rheumatoid Arthritis	December 2011	Phase 4
NCT00358683	UCB Pharma	Crohn´s Disease	November 2007	Phase 3
NCT00160706	UCB Pharma SA\|UCB Pharma	Crohn´s Disease	February 2004	Phase 3
NCT00993668	UCB Pharma	Rheumatoid Arthritis	September 2009	Phase 4
NCT00552058	UCB Pharma	Crohn Disease	March 2008	Phase 3
NCT00899678	UCB Celltech\|UCB Pharma	Crohn´s Disease	April 2009	Phase 2
NCT00753454	UCB Pharma	Rheumatoid Arthritis	September 2008	Phase 3
NCT04053881	UCB Biopharma SRL\|UCB Pharma	Plaque Psoriasis	August 21, 2019
NCT03016260	TcLand Expression S.A.\|European Commission	RheumatoId Arthritis	December 2016
NCT02151851	UCB Pharma SA, Belgium\|Parexel\|UCB Pharma	Rheumatoid Arthritis	July 2014	Phase 3
NCT01190410	UCB Pharma	Crohn´s Disease	August 2010	Phase 2
NCT02597829	Shafran Gastroenterology Center\|UCB Pharma	Crohn´s Disease	November 2015	Phase 4
NCT00152386	UCB Pharma	Rheumatoid Arthritis	February 2005	Phase 3
NCT00354367	UCB Pharma	Crohn Disease	January 2007	Phase 3
NCT01024647	Atlanta Gastroenterology Associates\|UCB Pharma	Crohn´s Disease	December 2009	Phase 4
NCT01213017	Oklahoma Medical Research Foundation\|UCB Pharma	Rheumatoid Arthritis	September 2010	Phase 3
NCT03414502	University of Nebraska	Rheumatoid Arthritis	August 2007	Phase 3
NCT00160641	UCB Pharma	Rheumatoid Arthritis	November 2005	Phase 3
NCT04123795	UCB Biopharma SRL\|UCB Pharma	Moderate Chronic Plaque Psoriasis\|Severe Chronic Plaque Psoriasis\|Mixed Guttate+Plaque Psoriasis	January 21, 2020	Phase 3
NCT04740814	UCB Biopharma SRL\|UCB Pharma	Rheumatoid Arthritis	February 11, 2021	Phase 1
NCT02505542	UCB BIOSCIENCES GmbH\|Parexel\|UCB Pharma	Axial Spondyloarthrithis\|Ankylosing Spondylitis	July 2015	Phase 3
NCT02346240	UCB Biopharma S.P.R.L.\|UCB Pharma	Psoriasis\|Plaque Psoriasis	February 11, 2015	Phase 3
NCT00175877	UCB Pharma	Rheumatoid Arthritis	June 2005	Phase 3
NCT00813774	UCB Pharma	Bioavailability Study on Healthy Volunteers	February 2008	Phase 1
NCT03051217	UCB Biopharma S.P.R.L.\|UCB Pharma	Moderate to Severe Psoriasis\|Generalized Pustular Psoriasis and Erythrodermic Psoriasis	February 21, 2017	Phase 2\|Phase 3
NCT04643483	UCB Biopharma SRL\|UCB Pharma	Crohn´s Disease	June 2021	Phase 3

Appearance

Liquid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.